Obesity Surgery

, Volume 17, Issue 2, pp 176–184 | Cite as

Resolution of Diabetes Mellitus and Metabolic Syndrome following Roux-en-Y Gastric Bypass and a Variant of Biliopancreatic Diversion in Patients with Morbid Obesity

  • Theodore K. Alexandrides
  • George Skroubis
  • Fotis Kalfarentzos


Obesity is associated with increased prevalence of type 2 diabetes mellitus (DM2) and metabolic syndrome and increased morbidity and mortality. Bariatric surgery results in significant and long-term weight loss. Two of the most effective and popular bariatric procedures are Roux-en-Y gastric bypass (RYGBP) and biliopancreatic diversion (BPD). The objective of this study was to investigate the effects of RYGBP and BPD-RYGBP, a variant of BPD with a lower rate of metabolic deficiencies than BPD, on DM2 and the major components of metabolic syndrome in patients with morbid obesity and DM2.


The prospective database of our unit, from June 1994 until May 2006, was analyzed and 137 patients with DM2 were found. 26 underwent RYGBP (BMI 46.1±2.9 kg/m2) and 111 BPD-RYGBP (BMI 59.7±10.6 kg/m2). 7 of the patients were on insulin (4.90%) and 37 on oral hypoglycemic agents (25.87%). Pre- and postoperative medications, and clinical and biochemical parameters were considered in the analysis. The mean follow-up was 26.39±21.17 months.


Excess weight loss was ∼70% after either procedure. DM2 resolved in 89% and 99% of the cases following RYGBP and BPD-RYGBP, respectively. 2 years after BPD-RYGBP all the patients had blood glucose <110 mg/dl, 95% had normal cholesterol, 92% normal triglycerides and 82% normal blood pressure. The respective values following RYGBP were 66%, 33%, 78% and 44%. Uric acid decreased significantly only after BPD-RYGBP. Liver enzymes improved in both groups.


RYGBP and BPD-RYGBP are safe and lead to normalization of blood glucose, lipids, uric acid, liver enzymes and arterial pressure in the majority of patients, although this variant of BPD was more effective than RYGBP.We suggest that further studies should also investigate its usefulness in patients with milder degrees of obesity, DM2 and metabolic syndrome.

Key words

Morbid obesity bariatric surgery diabetes metabolic syndrome gastric bypass biliopancreatic diversion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Astrup A, Finer N. Redefining type 2 diabetes: “diabesity” or “obesity dependent diabetes mellitus”? Obes Rev 2000; 1: 57–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Grundy SM, Brewer HB Jr, Cleeman JI et al. American Heart Association; National Heart, Lung and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Ash S, Reeves MM, Yeo S et al. Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomized trial. Int J Obes 2003; 27: 797–802.CrossRefGoogle Scholar
  6. 6.
    Paisey RB, Frost J, Harvey P et al. Five-year results of a prospective very low calorie diet or conventional weight loss program in type 2 diabetes. J Hum Nutr Diet 2002; 15: 121–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes — a systematic review. Diabetes Metab Res Rev 2004; 20: 438–45.PubMedCrossRefGoogle Scholar
  8. 8.
    Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724–37.PubMedCrossRefGoogle Scholar
  9. 9.
    Long SD, O’Brien K, MacDonald KG Jr et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care 1994; 17: 372–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Sjostrom L, Lindroos AK, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG et al. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003; 52: 1098–103.PubMedCrossRefGoogle Scholar
  12. 12.
    Scopinaro N, Marinari GM, Camerini GB et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome. A long-term follow-up study. Diabetes Care 2005; 28: 2406–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Kalfarentzos F, Dimakopoulos A, Kehagias I et al. Vertical banded gastroplasty versus standard or distal Roux-en-Y gastric bypass based on specific selection criteria in the morbidly obese: preliminary results. Obes Surg 1999; 9: 433–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Kalfarentzos F, Skroubis G, Kehagias I et al. A prospective comparison of vertical banded gastroplasty and Roux-en-Y gastric bypass in a non-superobese population. Obes Surg 2006; 16: 151–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalfarentzos F, Papadoulas S, Skroubis G et al. Prospective evaluation of biliopancreatic diversion with Roux-en-Y gastric bypass in the super obese. J Gastrointest Surg 2004; 8: 479–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Schauer PR, Burguera B, Ikramuddin S et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467–84.PubMedGoogle Scholar
  17. 17.
    Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance mechanisms and therapeutic implications. Diabetologia 2004; 47: 581–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Balsiger BM, Poggio JL, Mai J et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000; 4: 598–605.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Brien PE, Dixon JB. Laparoscopic adjustable gastric banding in the treatment of morbid obesity. Arch Surg 2003; 138: 376–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Heilbronn LK, Noakes M, Clifton PM. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr 2002; 21: 120–7.PubMedGoogle Scholar
  21. 21.
    Greco AV, Mingrone G, Giancaterini A et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51: 144–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Scopinaro N. Biliopancreatic diversion: Mechanisms of action and long-term results. Obes Surg 2006; 16: 683–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubino F, Gagner M, Gentileschi P. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240: 236–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239: 1–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Valverde I, Puente J, Martin-Duce A et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005; 15: 387–97.PubMedCrossRefGoogle Scholar
  26. 26.
    D’Alessio D, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882–E890.PubMedCrossRefGoogle Scholar
  27. 27.
    Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Service GJ, Thompson GB, Service FJ et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Adami GF, Cordera R, Camerini G et al. Long term normalization of insulin sensitivity following biliopancreatic diversion for obesity. Int J Obes 2004; 28: 671–3.CrossRefGoogle Scholar
  30. 30.
    Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol 2003; 284: G551–G557.PubMedGoogle Scholar
  31. 31.
    Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733–49.PubMedCrossRefGoogle Scholar
  32. 32.
    Lopez-Suarez A, Elvira-Gonzalez J, Bascunana- Quirell A et al. Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome. Med Clin (Barc) 2006; 126: 321–4.CrossRefGoogle Scholar
  33. 33.
    Frantzides CT, Carlson MA, Moore RE et al. Effect of body mass index on non-alcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery. J Gastrointest Surg 2004; 8: 849–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135: 48–58.PubMedCrossRefGoogle Scholar
  35. 35.
    Mattar SG, Velcu LM, Rabinovitz M et al. Surgicallyinduced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610–7.PubMedGoogle Scholar
  36. 36.
    Scopinaro N, Adami GF, Marinari GM et al. Biliopancreatic diversion. World J Surg 1998; 22: 936–46.PubMedCrossRefGoogle Scholar
  37. 37.
    MacDonald KG Jr, Long SD, Swanson MS et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Skroubis G, Anesidis S, Kehagias I et al. Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: Prospective comparison of the efficacy and the incidence of metabolic deficiencies. Obes Surg 2006; 16: 488–95.PubMedCrossRefGoogle Scholar
  39. 39.
    Skroubis G, Sakellaropoulos G, Pouggouras K et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg 2002; 12: 551–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  • Theodore K. Alexandrides
    • 1
  • George Skroubis
    • 2
  • Fotis Kalfarentzos
    • 3
    • 4
  1. 1.Associate Professor of Internal Medicine – Endocrinology, Head of Endocrine Division, Department of Internal MedicineSchool of Medicine, University of PatrasPatrasGreece
  2. 2.Lecturer of Surgery, Nutrition Support and Morbid Obesity Unit, Department of SurgerySchool of Medicine, University of PatrasPatrasGreece
  3. 3.Professor and Chairman of Surgery, Nutrition Support and Morbid Obesity Unit, Department of SurgerySchool of Medicine, University of PatrasPatrasGreece
  4. 4.Professor and Chairman, Department of SurgerySchool of Medicine, University of PatrasPatrasGreece

Personalised recommendations